SCHEMBL532572

SCHEMBL532572

NC(=O)C=CC1CCCC1

nearest known ligand 0.40

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 1/20 0.39
GRIN2B Q13224 1/20 0.39
EPHX1 P07099 3/20 0.34
GRIK1 P39086 2/20 0.32
GRIK2 Q13002 1/20 0.32
PADI4 Q9UM07 2/20 0.31
ALOX5 P09917 2/20 0.31
CES2 O00748 1/20 0.31
CES1 P23141 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL163417 0.98 GRIN1 (0.41) GRIN1GRIN2BEPHX1GRIK1GRIK2
SCHEMBL3114037 0.98 GRIN1 (0.41) GRIN1GRIN2BEPHX1GRIK1GRIK2
SCHEMBL4079497 0.98 GRIN1 (0.41) GRIN1GRIN2BEPHX1GRIK1GRIK2
SCHEMBL4743867 0.95
SCHEMBL730203 0.90 HDAC2 (0.34) GRIN1GRIN2B
SCHEMBL543403 0.90
SCHEMBL6360578 0.81 EPHX2 (0.33)
SCHEMBL730032 0.80 EPHX1 (0.34) EPHX1ALOX5CES2CES1
SCHEMBL30980070 0.80 EPHX1 (0.34) EPHX1ALOX5CES2CES1
SCHEMBL3260266 0.79 TSHR (0.38) EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202366-B2 Methods of promoting wound healing using CRM1 inhibitors Karyopharm Therapeutics Inc. (US) 2019-02-12 US claimed
WO-2014088850-A2 SHALE SWELLING INHIBITORS ISP INVESTMENTS INC. (US) 2014-06-12 WO claimed
EP-2414456-A1 DEGRADABLE POLYMER COMPOSITIONS AND USES THEREOF Isp Investments Inc. (US) 2012-02-08 EP claimed
EP-2346909-A1 POLYMERS DERIVED FROM N-VINYL FORMAMIDE, VINYL AMIDES OR ACRYLAMIDES, AND REACTION SOLVENT, AND THE USES THEREOF Isp Investments Inc. (US) 2011-07-27 EP claimed
WO-2010114761-A1 DEGRADABLE POLYMER COMPOSITIONS AND USES THEREOF ISP INVESTMENT INC. (US) 2010-10-07 WO claimed
WO-2010056934-A1 POLYMERS DERIVED FROM N-VINYL FORMAMIDE, VINYL AMIDES OR ACRYLAMIDES, AND REACTION SOLVENT, AND THE USES THEREOF ISP INVESTMENTS INC. (US) 2010-05-20 WO claimed
US-20250188201-A1 CATALYST FOR PHOTOCATALYTIC POLYMERIZATION REACTION, AND APPLICATION THEREOF BEIJING INSTITUTE OF FASHION TECHNOLOGY (CN) 2025-06-12 US disclosed
CN-116813823-A Supported catalyst, preparation method thereof and application thereof in photocatalytic polymerization 北京服装学院 2023-09-29 CN disclosed
WO-2023169566-A1 CATALYST FOR PHOTOCATALYTIC POLYMERIZATION REACTION, AND APPLICATION THEREOF 北京服装学院 2023-09-14 WO disclosed
US-11492432-B2 Resin for nanoimprinting, laminate containing resin for nanoimprinting, printed board containing resin for nanoimprinting, and method for producing nanoimprint substrate JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2022-11-08 US disclosed
US-20200223125-A1 RESIN FOR NANOIMPRINTING, LAMINATE CONTAINING RESIN FOR NANOIMPRINTING, PRINTED BOARD CONTAINING RESIN FOR NANOIMPRINTING, AND METHOD FOR PRODUCING NANOIMPRINT SUBSTRATE JAPAN SCIENCE & TECH AGENCY (JP) 2020-07-16 US disclosed
US-9452977-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2016-09-27 US disclosed
CN-105315224-A Cyclopentylacrylamide derivative KYORIN SEIYAKU KK 2016-02-10 CN disclosed
US-20150298387-A1 RESIN FOR NANOIMPRINTING, LAMINATE CONTAINING RESIN FOR NANOIMPRINTING, PRINTED BOARD CONTAINING RESIN FOR NANOIMPRINTING, AND METHOD FOR PRODUCING NANOIMPRINT SUBSTRATE JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2015-10-22 US disclosed
US-8946440-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2015-02-03 US disclosed
WO-2014088850-A2 SHALE SWELLING INHIBITORS ISP INVESTMENTS INC. (US) 2014-06-12 WO disclosed
EP-2542089-A1 NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF Karyopharm Therapeutics, Inc. (US) 2013-01-09 EP disclosed
WO-2011109799-A1 NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF KARYOPHARM THERAPEUTICS, INC. (US) 2011-09-09 WO disclosed
EP-2346909-A1 POLYMERS DERIVED FROM N-VINYL FORMAMIDE, VINYL AMIDES OR ACRYLAMIDES, AND REACTION SOLVENT, AND THE USES THEREOF Isp Investments Inc. (US) 2011-07-27 EP disclosed
WO-2010056934-A1 POLYMERS DERIVED FROM N-VINYL FORMAMIDE, VINYL AMIDES OR ACRYLAMIDES, AND REACTION SOLVENT, AND THE USES THEREOF ISP INVESTMENTS INC. (US) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10202366-B2 Methods of promoting wound healing using CRM1 inhibitors XPO1, XPA, ERCC2 GRIN1 1347/4885GRIN2B 3441/4885EPHX1 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.